Drugs / dexloxiglumide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00303264 | May 2006 → Aug 2007 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00220090 | Jul 2003 → Sep 2006 | irritable bowel syndrome | Rottapharm | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dexloxiglumide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00303264 ↗ |
| Known as | CR-2017 | ChEMBL registry synonym — accepted as the source's own label CHEMBL550781 ↗ |
| Known as | Dexloxiglumida | ChEMBL registry synonym — accepted as the source's own label CHEMBL550781 ↗ |
| Known as | Loxiglumide (r)-form | ChEMBL registry synonym — accepted as the source's own label CHEMBL550781 ↗ |
| Action | Inhibit | “Cholecystokinin A receptor antagonist” CHEMBL550781 ↗ |
| Modality | Small molecule | — CHEMBL550781 ↗ |
| Route | Oral | “Dexloxiglumide is an oral potent and selective antagonist of CCK1-receptors.” NCT00220090 ↗ |
| Target | CCKAR | “Cholecystokinin A receptor antagonist” CHEMBL550781 ↗ |